已关闭
收藏
| Catalog No. | KDD87601 | ||||||||||||||||||||||||||||||||||||||||||
| Product name | Itolizumab ELISA Kit | ||||||||||||||||||||||||||||||||||||||||||
| Description | PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD6 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Itolizumab in the sample competitively binds to the pre-coated protein with biotin-labeled Itolizumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Itolizumab bound in the initial step. The color development is stopped and the intensity of the color is measured. | ||||||||||||||||||||||||||||||||||||||||||
| Applications | Used for the quantitative determination of Itolizumab concentration in serum and plasma. | ||||||||||||||||||||||||||||||||||||||||||
| Stability and Storage | When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. | ||||||||||||||||||||||||||||||||||||||||||
| Detection method | Colorimetric | ||||||||||||||||||||||||||||||||||||||||||
| Precision | Intra-Assay Precision (Precision within an assay): <20% Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision. Inter-Assay Precision (Precision between assays): <20% Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
| ||||||||||||||||||||||||||||||||||||||||||
| Sample type | Plasma, Serum | ||||||||||||||||||||||||||||||||||||||||||
| Assay type | Quantitative | ||||||||||||||||||||||||||||||||||||||||||
| Sensitivity | 69.97 ng/mL | ||||||||||||||||||||||||||||||||||||||||||
| Range | 234.38 - 15,000 ng/mL | ||||||||||||||||||||||||||||||||||||||||||
| Recovery | 80-120% | ||||||||||||||||||||||||||||||||||||||||||
| Background | Itolizumab, a humanized anti-CD6 monoclonal antibody, is a new molecule that acts by immunomodulating the CD6 molecule. CD6 is a co-stimulatory molecule required for optimal T-cell stimulation by the antigen-presenting cells. This step is crucial in T-cell proliferation to form Th1 and Th17 cells, which play a major role in the pathogenesis of psoriasis. | ||||||||||||||||||||||||||||||||||||||||||
| Alternative Names | T1h, CAS: 1116433-11-4 | ||||||||||||||||||||||||||||||||||||||||||
| Note | For Research Use Only. | ||||||||||||||||||||||||||||||||||||||||||